Your browser doesn't support javascript.
loading
Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
Orlovic, Martina; Magni, Tiziana; Lukyanov, Vasily; Guerra, Ines; Madoni, Alessandra.
Afiliación
  • Orlovic M; Chiesi Farmaceutici SpA, Parma, Italy. Electronic address: m.orlovic@chiesi.com.
  • Magni T; Chiesi Farmaceutici SpA, Parma, Italy. Electronic address: t.magni@chiesi.com.
  • Lukyanov V; IQVIA Solutions BV, Amsterdam, the Netherlands. Electronic address: vasily.lukyanov@mail.ru.
  • Guerra I; IQVIA Solutions BV, Amsterdam, the Netherlands. Electronic address: ines.guerra@iqvia.com.
  • Madoni A; Chiesi Farmaceutici SpA, Parma, Italy. Electronic address: a.madoni@chiesi.com.
Respir Med ; 201: 106934, 2022 09.
Article en En | MEDLINE | ID: mdl-35872377
BACKGROUND: In patients with asthma that is uncontrolled by a medium- or high-dose inhaled corticosteroid (ICS) plus long-acting ß2-agonist (LABA), a maintenance therapy option is the addition of a long-acting muscarinic agonist, either via multiple inhalers, or single-inhaler triple therapy (SITT). One SITT is the extrafine formulation of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G). We used data from two 52-week clinical trials (TRIMARAN and TRIGGER), both conducted in adults with asthma uncontrolled by ICS/LABA, to investigate the cost-effectiveness of BDP/FF/G. METHODS: A Markov cohort state transition model (focusing on exacerbations) was used to investigate the cost-effectiveness of medium- or high-dose BDP/FF/G vs medium- or high-dose BDP/FF, and high-dose BDP/FF/G vs high-dose BDP/FF + tiotropium. The model analysed cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER), and was developed from the England National Health Service perspective (2020 costs). Uncertainty of the inputs was estimated using one-way and probabilistic sensitivity analyses. RESULTS: Both medium- and high-dose BDP/FF/G were cost-effective vs BDP/FF, with ICERs of £12,224 and £15,587 per QALY gained. High-dose BDP/FF/G was dominant vs BDP/FF + tiotropium, as it was both cheaper and gained QALYs. Sensitivity analyses were consistent with the base model: medium- and high-dose BDP/FF/G had 94.3% and 88.3% likelihoods to be cost-effective vs BDP/FF; high-dose BDP/FF/G had 100% likelihood to be a dominant strategy vs BDP/FF + tiotropium. CONCLUSIONS: Both medium- and high-dose BDP/FF/G were cost-effective vs medium- and high-dose BDP/FF in adults with asthma that was uncontrolled by ICS/LABA. In addition, high-dose BDP/FF/G was a dominating strategy to high-dose BDP/FF + tiotropium. CLINICALTRIALS: GOV: NCT02676076 and NCT02676089.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Beclometasona Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Límite: Adult / Humans Idioma: En Revista: Respir Med Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Beclometasona Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Límite: Adult / Humans Idioma: En Revista: Respir Med Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido